Cord Blood and Stem Cell Research: A New Frontier for Bioethical Debate. American Academy of Pediatrics. Nutt J. 2010. Repeated phencyclidine exposure reduces NMDA receptor function and causes deficits in reversal learning and locomotion. The American Journal of Pathology. 177(2): 735–742. Nutt J, Phillips N, et al. 2017. Effects of low-dose haloperidol on cognitive and motor symptoms in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. The Lancet Psychiatry. 4(1): 45–56. Nutt J, Rees G, Ginieri C, et al. 2011. Clinical trial of the NMDA receptor antagonist, memantine, for the treatment of dyskinesia in Parkinson’s disease. Annals of Neurology. 72(1): 139–146. O’Donnell-Tormey M. 2014. Neurotransmitters in psychiatric disorders: is it possible to understand the complex and contradictory roles of 5-HT and DA? Expert Review of Neurotherapeutics. 14(1): 1–24. Pacula R. 2017. “The Future is Now”: a Decade-Long Celebration of the Breakthroughs and Promise of Human Stem Cell Research. Science. Park KW, Koeberle T, et al. 2012. Long-term safety and efficacy of a continuous intrathecal baclofen infusion in patients with severe, chronic, treatment-refractory spasticity. Neurology. 79(2): 188–194. Pfaff DW, Jain DK. 2012. Is adult hippocampal neurogenesis necessary for normal cognitive function? Nature Reviews Neuroscience. 13(6): 405–416. Phillips N, Nutt J. 2009. Effects of antipsychotic drugs on NMDA receptor transmission in the CNS: relevance for the treatment of schizophrenia. British Journal of Psychiatry. 195(2): 99–106. Phillips N, Nutt J. 2011. Effects of haloperidol on neural activity and behaviour in a rodent model of psychosis: relevance to the management of antipsychotic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35(9): 1189–1197. Phillips N, Javitt DC, et al. 2016. Effects of a clinically-relevant dose of antipsychotic drugs on NMDAR subunit availability in healthy volunteers and in patients with schizophrenia. Neuroscience & Biobehavioral Reviews. 77: 35–46. Pramod M, Poddar AK, Ghosh S, et al. 2016. A systematic review and meta-analysis of high dose of methylphenidate and stimulants on cognition in attention-deficit/hyperactivity disorder: Effect of duration of stimulant use. BMC Psychiatry. 16: 35. Pramod M, Poddar AK, et al. 2017. High dose methylphenidate improves immediate and delayed story recall and attention in children with attention-deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 26(2): 121–132. Qian Z, Yang Y, et al. 2018. Effects of a 4-day long course of methylphenidate treatment on visual processing of emotional faces in children with attention-deficit hyperactivity disorder. The Journal of Neuroscience. 38(35): 7861–7868. Ramadan S, Hakim R, et al. 2017. Long-term efficacy and safety of paliperidone extended release in adults with schizophrenia: a post-hoc analysis. The New England Journal of Medicine. 376(4): 315–324. Rao A, Tardif J, et al. 2012. Chronic morphine treatment impairs spatial learning and increases cell proliferation in the subventricular zone. Hippocampus. 22(12): 893–908. Razali M, Rani V, et al. 2015. Effects of methylphenidate treatment on cognition, executive functions and attention in children with ADHD: a meta-analysis. Frontiers in Pediatrics. 6: 23. Reimers A, Leinsalu K, et al. 2016. Treatment with lisdexamfetamine dimesylate in adults with attention deficit hyperactivity disorder: a randomized, placebo-controlled trial. Journal of the American Medical Association. 315(19): 2001–2010. Sannerud K, Ketter T, et al. 2018. Effects of high dose atomoxetine on motor function in ADHD: Results from a randomized, double-blind, multicenter clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 57(1): 67–77. Schlaggar BL, Zaharia L, et al. 2016. Moderate sleep deprivation impairs learning, but only if consolidated during wakefulness. Neuron. 90(2): 345–352. Scott R. 2018. Brain Reward Circuitry and Addictive Drugs: Mechanisms for Addictive Drugs of Abuse. Frontiers in Pharmacology. 7: 58. Sherva G, Griesinger C, et al. 2014. Replication and extension of the initial double-blind, placebo-controlled methylphenidate (Ritalin) in attention-deficit/hyperactivity disorder trial in adults with cognitive impairment. Journal of Attention Disorders. 20(6): 467–475. Simon MA, Gopal S, Prasad D, et al. 2017. Effect of atomoxetine on cerebrospinal fluid monoamine metabolite levels and brain structure in youth with ADHD. American Journal of Psychiatry. 174(1): 80–86. Simpson AJ, Cui J, et al. 2012. Chronic methylphenidate treatment in the neonatal period increases parvalbumin-expressing GABA neurons in the mouse cortex and hippocampus. European Journal of Neuroscience. 37(1): 105–110. Singh JP, Sagar PC, et al. 2010. Pharmacological intervention and cognitive training: a possible road map for early psychosis intervention. Frontiers in Psychiatry. 1: 5. Sokhadze S, Puri I, et al. 2015. Long-term safety and tolerability of extended release atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: pooled analysis of short-term studies. The Journal of Clinical Psychopharmacology. 35(1): 63–71. Sørensen E, Hildebrandt R, et al. 2017. The long-term safety of atomoxetine and methylphenidate in the treatment of attention deficit hyperactivity disorder: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Academy of Child & Adolescent Psychiatry. 56(3): 230–245. Stevenson HB. 2016. The History of Methamphetamine Abuse. Cambridge: Cambridge University Press. Stevenson HB, Bijl N, et al. 2018. Risks and benefits of stimulant medication to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Lancet Psychiatry. 5(6): 632–644. Sumiyoshi K, Yamamoto N, et al. 2010. The Effect of Ritalin on Children’s Attention Problems at Home and at School: Results of a Prospective Study. Psychiatry Research. 189(2): 173–178. Taylor M, Reyes-Velarde R. 2017. Atomoxetine in the treatment of attention-deficit/hyperactivity disorder: pharmacology, indications, and clinical use. Expert Review of Neurotherapeutics. 17(10): 1127–1152. Thornton JL. 2016. Neurobiological Basis of Antidepressant Action: An Overview of Monoaminergic and Non-Monoaminergic Neuroplasticity. Trends in Neurosciences. 39(3): 188–197. Tuch M, Gjedde A, et al. 2018. Is a new paradigm of ADHD treatment being obscured? A meta-analysis of methylphenidate in children and adolescents with ADHD. Brain Research. 2204: 85–94. Ullén A, Sandgren K, et al. 2009. Effects of treatment duration on stimulant response, tolerance, and withdrawal in children with ADHD: a meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry. 48(6): 591–599. Valera R, Fernández-Sola J, et al. 2015. Neural correlates of cognitive control in medication-naïve youth with ADHD: a randomized trial of methylphenidate versus atomoxetine. Journal of Abnormal Child Psychology. 43(5): 637–651. Van Kammen DP, Voon V, et al. 2015. The long-term effects of neurostimulants on the development of cardiovascular disease. European Heart Journal Cardiovascular Pharmacotherapy. 17(3): 271–279. Van Meter JM, Kowalski JM, et al. 2012. Insufficient sleep causes brain atrophy in young adult rhesus monkeys: a model for accelerated brain aging and neurodegenerative disease. Neurobiology of Disease. 55(4): 464–470. Van Wouwe JN, Vand